May 15, 2006 – Cepheid (Nasdaq: CPHD), a molecular diagnostics company, announced the European release of its Epstein-Barr virus assay for clinical diagnostic use on its SmartCycler System. The Smart EBV assay is intended for detection of Epstein-Barr virus. EBV infection is associated with development of a serious complication of bone marrow or solid-organ transplantation in which uncontrolled growth of lymphatic tissue can become life-threatening.
The SmartCycler System is a real-time PCR testing platform that the company says can deliver test results from prepared biological samples in approximately 30-40 minutes.